Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Terns Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/08/2023 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates - Terns reported positive top-line data from the Phase 2a DUET trial of TERN-501 in NASH, with TERN-501 meeting all primary and secondary endpoints - TERN-701 Phase 1 clinical trial for CML on track to initiate in second half of 2023; enrollment progress from ongoing China Phase 1 clinical trial presented at 2023 ASCO Annual Meeting - TERN-601 program in obesity highlighted in preclinical data presented at ADA’s 83rd Annual Scientific Meeting; on track to initiate Phase 1 clinical trial in second half of 2023 - Cash, cash equivalents and marketable securities of $286 million expected to provide runway into 2026 FOSTER CITY, Calif., August 8, 2023 – Terns Pharmaceuticals, Inc. , a clinical-stage biopha..."
08/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Terns Pharmaceuticals Announces Leadership Transition"
05/15/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Terns Pharmaceuticals, Inc. $150,000,000 SHARES of Common Stock, Par Value $0.0001 SALES AGREEMENT",
"Letter re: Prospectus Supplement to Registration Statement on Form S-3"
05/15/2023 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates - Top-line data from Phase 2a DUET clinical trial of TERN-501 in NASH expected in third quarter of 2023 - TERN-701 Phase 1 trial for CML on track to initiate in the U.S. in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at the 2023 ASCO Annual Meeting - TERN-601 program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with initial proof of concept data anticipated in 2024 - Cash, cash equivalents and marketable securities of $298 million expected to provide runway into 2026 FOSTER CITY, Calif., May 15, 2023 – Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product ca..."
03/27/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences Completes enrollment in Phase 2a DUET clinical trial of TERN-501 as a treatment for NASH with top-line results expected in third quarter of 2023 On track to initiate U.S. clinical trial for TERN-701 in CML in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at a major upcoming oncology conference IND-enabling activities for TERN-601 ongoing; on track to initiate first-in-human clinical trial in obesity in second half of 2023 Cash and cash equivalents expected to provide runway into 2026 FOSTER CITY, Calif., March 2, 2023 -- Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule p..."
01/05/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference Plans to advance diverse pipeline of five disclosed programs in oncology and metabolic diseases Expects to initiate proof of concept trials in CML and obesity and to report top-line data from DUET, the first trial assessing THR-β agonist as monotherapy and in combination with FXR agonist for NASH Cash and cash equivalents, together with the $112 million from proceeds raised in December 2022, expected to provide runway into 2026 FOSTER CITY, Calif., Jan. 5, 2023 -- Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non..."
11/09/2022 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights • Terns plans to initiate U.S. clinical trial for TERN-701 in CML in second half of 2023 • Positive data from Phase 1 trial of TERN-501 in NASH presented at AASLD 2022, with top-line data from Phase 2a DUET trial expected in second half of 2023 • IND-enabling activities for TERN-601 remain on track with plans to initiate first-in-human clinical trial in obesity in 2023 • Cash and equivalents of $187 million provides runway into 2025, including three clinical data readouts from Terns’ three lead programs: TERN-701, TERN-601 and TERN-501 FOSTER CITY, Calif., Nov. 9, 2022 -- Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of sm..."
08/16/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights • TERN-701 advances into Phase 1 trial for CML in China • IND-enabling activities for TERN-601 remain on track; Phase 1 obesity trial initiation expected in 2023 • Initiated dosing of TERN-501 Phase 2a DUET combo clinical trial for NASH; top-line data expected in second half of 2023 • Cash and equivalents of $140 million provides runway into 2025, supporting three expected clinical trial readouts across three product candidates and three indications FOSTER CITY, Calif., August 8, 2022 – Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesi..."
07/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors FOSTER CITY, Calif., July 27, 2022 – Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases such as non-alcoholic steatohepatitis , obesity and cancer, today announced the appointment of Radhika Tripuraneni, M.D., M.P.H. to the Company’s Board of Directors. Dr. Tripuraneni serves as the Chief Development Officer of Prothena Corporation plc and brings to the Terns Board of Directors more than 15 years of experience in drug development. “Terns’ approach of discovering and developing next-generation small molecules for clinically de-risked targets in indications with significant unmet need is an ..."
06/17/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/21/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights -Top-line data readout from TERN-201 clinical trial in NASH expected in March 2022 -Initiation of Terns’ first NASH trial of TERN-501 alone and in combination with TERN-101 planned for first half of 2022 with top-line data expected in second half of 2023 -Nominated TERN-601 development candidate with the goal of initiating a first-in-human clinical trial in 2023 -Cash and equivalents of $166 million provides runway into 2024"
01/19/2022 8-K Other Events  Interactive Data
11/09/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501 TERN-501 demonstrated significant effects on key pharmacodynamic marker of THR-β engagement linked to NASH histologic efficacy TERN-501 was generally safe and well-tolerated with predictable pharmacokinetic profile with low variability Terns plans to initiate first FXR/THR-β agonist combination trial in NASH in 1H 2022 FOSTER CITY, Calif., November 9, 2021 – Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases, today reported positive top-line results from a Phase 1 clinica..."
09/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors FOSTER CITY, Calif., Sept. 28, 2021 – Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases, today announced the appointment of Ann E. Taylor, M.D., to the Company’s Board of Directors. Dr. Taylor previously served as the Chief Medical Officer of AstraZeneca plc and brings to the Terns Board of Directors more than 35 years of experience in drug development. “NASH remains an area of significant unmet need and I believe Terns’ approach, which seeks to combine best-in-class molecules with clinically valida..."
08/16/2021 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights -Top-line data from ongoing Phase 1 proof of concept clinical trial of TERN-501 expected in 4Q 2021 -Top-line data readout from Part 1 of ongoing AVIATION Trial of TERN-201 expected in 1H 2022 -Cash and equivalents of $185.1 million provides runway into 2024"
06/14/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
03/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : February 23, 2021 Terns Pharmaceuticals, Inc. Delaware 001-39926 98-1448275 1065 East Hillsdale Blvd., Suite 100 Foster City, California 94404 Registrant's telephone number, including area code: 525-5535 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#..."
02/09/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : February 9, 2021 Terns Pharmaceuticals, Inc. Delaware 001-39926 98-1448275 1065 East Hillsdale Blvd., Suite 100 Foster City, California 94404 Registrant's telephone number, including area code: 525-5535 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#9...",
"Amended and Restated Certificate of Incorporation of Terns Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Terns Pharmaceuticals, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy